Filter results

Clinical Studies

Open

Contact Us for the Latest Status

Closed for Enrollment

  • KT-US-471-0114, A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Subjects With Refractory Large B-Cell Lymphoma (ZUMA-14) Jacksonville, Fla.

    The primary objective of this study is to estimate the safety and effectiveness of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.

  • Mapping the Dynamic Response of the Immune System in Lymphoma Patients Starting Chemo-immunotherapy (MDRISLPSC) Rochester, Minn.

    The study aims to determine whether the baseline immune profile detected in the peripheral blood of patients with lymphoma differs from that of age- and sex-matched controls.
     

  • Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma Rochester, Minn.

    This randomized phase II trial studies how well obinutuzumab with or without PI3K-delta inhibitor TGR-1202, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. PI3K-delta inhibitor TGR-1202 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving obinutuzumab with or without PI3K-delta inhibitor TGR-1202, lenalidomide, or combination chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.

.